Abnormal metabolism and synthesis of lipids is involved in a variety of diseases, including cancer, diabetes, neurodegenerative diseases, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and cardiovascular diseases. Several small molecule inhibitors are used to fight lipid metabolic dysfunction. However, it is unavoidable that the inhibitors are short-lived or nonspecifically distributed in the body after injection or oral administration, and ultimately, only a small portion of the administered drugs bind to the target. Therefore, designing drug delivery systems to target the regulation of lipid metabolism is considered to be a promising strategy for the effective treatment of the above diseases. Moreover, the clinical significance of lipid-based mechanisms has been evaluated, and alterations in lipid levels in serum can affect the prognosis of patients. The physiological microenvironment remodeling and function of the immune system are also modulated by lipid metabolism in diseases. The aim of this Collection is to encourage submissions incorporating interdisciplinary approaches that construct advanced nanoplatforms to effectively deliver chemotherapeutic drugs, proteins, biomacromolecules, siRNA, mRNA and other regulators. In addition, the latest advances, emerging trends and strategies in the areas of lipid-related mechanisms and the mutual interactions between lipids and nanoparticles are also welcome. This Collection provides a platform for communication and discussion of the pharmacological mechanism of nanobiotechnology and lipid metabolism.
Keywords: Nanodrug delivery system, lipid metabolism, fatty acid, small molecule inhibitor, gene, metabolic diseases
The topics of interest include but are not limited to:
• Nanoplatforms of lipid metabolism related regulators and their evaluation in vitro and in vivo
• Delivery of molecules, natural products, or nucleic acids to treat cancer, diabetes, neurodegenerative diseases, NAFLD, NASH, cardiovascular diseases, etc., via reversal of abnormal lipid metabolic dysfunction
• Molecular pathways of nanodrug delivery systems regulating lipid synthesis and metabolism in metabolic diseases
• Mutual interactions between intracellular lipids and nanoparticles
• Effect of nanoparticles and materials on lipid metabolism
Questions to be answered:
• Whether the nanomaterials themselves affect intracellular lipid synthesis and metabolism?
• Which specific molecular pathways are involved in the drug delivery systems that regulate lipid synthesis and metabolism in diseases?
• Are there any novel strategies to target lipid metabolism by using natural products?
• How exactly can drug delivery systems affect the response of cells to therapy by regulating lipid metabolism?
• Challenges and limitations associated with nanomaterial-based drug delivery systems targeting lipid metabolism
